GarryMenzel

Dr Menzel was previously the founding President and Chief Executive Officer of TCR2 Therapeutics (Nasdaq:TCRR), leading the company from concept to clinical success with novel immunotherapies for solid tumors, before its strategic merger with Adaptimmune (Nasdaq:ADAP). He is also a founding board member of oncology company Black Diamond Therapeutics (Nasdaq:BDTX) and was appointed to the board of genetic disease company Stoke Therapeutics (Nasdaq:STOK). Prior to TCR2, he served in other operating roles as Chief Financial Officer of Fortune 500 company DaVita Healthcare (NYSE:DVA) and as Chief Operating Officer of microRNA company Regulus Therapeutics (Nasdaq:RGLS).

Dr Menzel has also held advisory roles on Wall Street in building the global biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain where he worked with companies from a broad spectrum of industries to develop and implement strategies that create sustainable value.

Dr Menzel earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a M.B.A. from the Stanford Graduate School of Business and a Bachelor of Science degree, with honors, in Biochemistry from Imperial College.

He served in the British Armed Forces and engages in a number of adventure sports including high altitude mountaineering and scuba diving.